This adaptability of CSCs is corroborated by ablation studies and lineage tracing in human colorectal cancer mouse models and organoid configurations, where research spearheaded by Shimokawa and Modrusan revealed that differentiated tumor cells could reacquire a LGR5+ state, indicative of colorectal cancer stem cell markers, and regain proliferative abilities following the targeted elimination of LGR5+ cells through cancer therapeutics or CRISPR editing techniques 13, 37. This evidence concerns the gene LGR5 and neoplasm.